LBO France announced the sale of Dutscher Group, a European laboratory supply distributor, to growth equity firm Vivo Capital in a secondary transaction disclosed January 9. No purchase price was reported. The exit closes LBO France's hold on the Brumath, France-based business, which distributes consumables and equipment to research laboratories across Europe.
Dutscher operates as a regional consolidator in the €12 billion European laboratory supply market, a segment dominated by Fisher Scientific and VWR but fragmented below the top tier. LBO France acquired the company in a platform investment during the post-pandemic laboratory buildout cycle, when life science capital expenditure ran 18% above 2019 levels through 2022. The firm did not disclose entry valuation or hold period in its press materials. Vivo Capital, a Palo Alto-based specialist in life science and healthcare growth equity with $8.2 billion under management, structured the transaction as a control purchase, signaling a platform bet rather than a minority growth stake.
The timing reflects two forces. First, European laboratory supply chains remain under pressure from procurement consolidation at pharmaceutical multinationals, which are centralizing vendor relationships to extract price concessions. Dutscher's regional footprint positions it as a second-tier supplier vulnerable to margin compression unless it scales distribution density or adds proprietary product lines. Second, life science-focused allocators are paying premiums for European distribution assets with embedded customer data, which can be leveraged into higher-margin value-added services like inventory management software or just-in-time delivery logistics. Vivo's entry suggests the firm sees Dutscher as underpenetrated in digital service revenue, a line that typically carries 40-55% gross margins versus 18-24% on consumables distribution.
This marks the second material European laboratory supply exit in six months. In August, Nordic Capital sold Laborie to a consortium led by Goldman Sachs Asset Management for approximately €1.3 billion, pricing the business at 14.2x trailing EBITDA. That multiple set a benchmark for scaled distribution platforms with recurring consumable revenue. Dutscher's undisclosed valuation likely came in below that range given its smaller European footprint and concentration risk in France, which accounts for an estimated 60-65% of revenue. The absence of a disclosed price also suggests LBO France may have structured seller financing or retained a minority roll to bridge a valuation gap, a common feature in secondary sales where growth visibility is ambiguous.
Operators should watch whether Vivo files for debt financing in the next 30-45 days, which would clarify leverage multiples and suggest acquisition appetite for bolt-on targets. Worth noting: Dutscher competes directly with Avantor in France, which has been pruning low-margin distributor relationships since its $4.6 billion VWR integration completed in 2023. If Avantor exits tertiary customer segments, Dutscher becomes a natural consolidator for orphaned accounts.
LBO France now holds 17 active portfolio companies across mid-market industrials and business services in Europe. The Dutscher exit removes one of its longest-tenured holdings and frees capital for deployment during a period when French mid-market deal flow is running 22% below 2021 levels due to financing costs. Vivo's willingness to write a control check into European distribution infrastructure signals continued appetite among U.S. life science specialists for non-core geographies, provided the asset offers a clear path to margin expansion through operational leverage or service line migration.